Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
J Appl Crystallogr ; 54(Pt 4): 1034-1046, 2021 Aug 01.
Article de Anglais | MEDLINE | ID: mdl-34429718

RÉSUMÉ

A novel capillary-based microfluidic strategy to accelerate the process of small-molecule-compound screening by room-temperature X-ray crystallography using protein crystals is reported. The ultra-thin microfluidic devices are composed of a UV-curable polymer, patterned by cleanroom photolithography, and have nine capillary channels per chip. The chip was designed for ease of sample manipulation, sample stability and minimal X-ray background. 3D-printed frames and cassettes conforming to SBS standards are used to house the capillary chips, providing additional mechanical stability and compatibility with automated liquid- and sample-handling robotics. These devices enable an innovative in situ crystal-soaking screening workflow, akin to high-throughput compound screening, such that quantitative electron density maps sufficient to determine weak binding events are efficiently obtained. This work paves the way for adopting a room-temperature microfluidics-based sample delivery method at synchrotron sources to facilitate high-throughput protein-crystallography-based screening of compounds at high concentration with the aim of discovering novel binding events in an automated manner.

2.
J Biol Chem ; 295(39): 13516-13531, 2020 09 25.
Article de Anglais | MEDLINE | ID: mdl-32723867

RÉSUMÉ

Prion disease is a rapidly progressive neurodegenerative disorder caused by misfolding and aggregation of the prion protein (PrP), and there are currently no therapeutic options. PrP ligands could theoretically antagonize prion formation by protecting the native protein from misfolding or by targeting it for degradation, but no validated small-molecule binders have been discovered to date. We deployed a variety of screening methods in an effort to discover binders of PrP, including 19F-observed and saturation transfer difference (STD) NMR spectroscopy, differential scanning fluorimetry (DSF), DNA-encoded library selection, and in silico screening. A single benzimidazole compound was confirmed in concentration-response, but affinity was very weak (Kd > 1 mm), and it could not be advanced further. The exceptionally low hit rate observed here suggests that PrP is a difficult target for small-molecule binders. Whereas orthogonal binder discovery methods could yield high-affinity compounds, non-small-molecule modalities may offer independent paths forward against prion disease.


Sujet(s)
Benzimidazoles/pharmacologie , Maladies à prions/traitement médicamenteux , Protéines prion/antagonistes et inhibiteurs , Bibliothèques de petites molécules/pharmacologie , Benzimidazoles/composition chimique , Découverte de médicament , Évaluation préclinique de médicament , Humains , Spectroscopie par résonance magnétique , Maladies à prions/métabolisme , Protéines prion/métabolisme , Bibliothèques de petites molécules/composition chimique
3.
AMIA Jt Summits Transl Sci Proc ; 2017: 522-530, 2017.
Article de Anglais | MEDLINE | ID: mdl-28815152

RÉSUMÉ

The physicians' biographical pages are essential in providing information about physicians' specialties. However, physicians may not have biographical pages or the current pages are not comprehensive. We hypothesize that physicians' specialty information can be mined from Electronic Medical Records (EMRs) of their patients. We proposed an automated physician specialty populating (PSP) system that analyzes physician-ascertained diagnoses in EMRs, aggregates them to an appropriate granularity based on the current biographical pages, and populates the biographical pages accordingly. In this study, we applied the system using EMR data from Mayo Clinic and evaluated the system using the current biographical pages regarding various ranking strategies. Preliminary results demonstrated that using EMR data is a scalable and systematic way to populate physicians' biographical pages.

4.
PLoS Genet ; 11(5): e1005231, 2015 May.
Article de Anglais | MEDLINE | ID: mdl-25996830

RÉSUMÉ

Mutations in the human LMNA gene cause muscular dystrophy by mechanisms that are incompletely understood. The LMNA gene encodes A-type lamins, intermediate filaments that form a network underlying the inner nuclear membrane, providing structural support for the nucleus and organizing the genome. To better understand the pathogenesis caused by mutant lamins, we performed a structural and functional analysis on LMNA missense mutations identified in muscular dystrophy patients. These mutations perturb the tertiary structure of the conserved A-type lamin Ig-fold domain. To identify the effects of these structural perturbations on lamin function, we modeled these mutations in Drosophila Lamin C and expressed the mutant lamins in muscle. We found that the structural perturbations had minimal dominant effects on nuclear stiffness, suggesting that the muscle pathology was not accompanied by major structural disruption of the peripheral nuclear lamina. However, subtle alterations in the lamina network and subnuclear reorganization of lamins remain possible. Affected muscles had cytoplasmic aggregation of lamins and additional nuclear envelope proteins. Transcription profiling revealed upregulation of many Nrf2 target genes. Nrf2 is normally sequestered in the cytoplasm by Keap-1. Under oxidative stress Nrf2 dissociates from Keap-1, translocates into the nucleus, and activates gene expression. Unexpectedly, biochemical analyses revealed high levels of reducing agents, indicative of reductive stress. The accumulation of cytoplasmic lamin aggregates correlated with elevated levels of the autophagy adaptor p62/SQSTM1, which also binds Keap-1, abrogating Nrf2 cytoplasmic sequestration, allowing Nrf2 nuclear translocation and target gene activation. Elevated p62/SQSTM1 and nuclear enrichment of Nrf2 were identified in muscle biopsies from the corresponding muscular dystrophy patients, validating the disease relevance of our Drosophila model. Thus, novel connections were made between mutant lamins and the Nrf2 signaling pathway, suggesting new avenues of therapeutic intervention that include regulation of protein folding and metabolism, as well as maintenance of redox homoeostasis.


Sujet(s)
Protéines et peptides de signalisation intracellulaire/métabolisme , Lamine A/génétique , Dystrophies musculaires/génétique , Facteur-2 apparenté à NF-E2/métabolisme , Transduction du signal , Protéines adaptatrices de la transduction du signal/génétique , Protéines adaptatrices de la transduction du signal/métabolisme , Animaux , Noyau de la cellule , Drosophila/génétique , Drosophila/métabolisme , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes , Homéostasie , Protéines et peptides de signalisation intracellulaire/génétique , Protéine-1 de type kelch associée à ECH , Lamine A/métabolisme , Muscles squelettiques/métabolisme , Mutation , Facteur-2 apparenté à NF-E2/génétique , Lamina nucléaire/génétique , Lamina nucléaire/métabolisme , Stress oxydatif , Conformation des protéines , Pliage des protéines , Séquestosome-1
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE